MAP3K5 and metabolic dysfunction-associated steatohepatitis: At present, the development of ASK1 inhibitor GS4997 has entered phase III clinical trials [183], but its two key clinical trials for the treatment of NASH have failed one after another, casting a shadow over the development of drugs for this target.